| Active substance | Bevacizumab |
| Holder | nv Roche sa |
| Status | Closed |
| Indication | in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, in adult patients with persistent, recurrent, or metastatic carcinoma of the cervix |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 22/09/2015 |
Avastin®
Last updated on 13/09/2024